Astellas Pharma and Vical asserts negative Phase 3 Clinical Trial results for ASP0113 for CMV-HSCT recipients Read more
Agenus launches its Clinical Trial combination of its anti-CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) antibodies Read more
AstraZeneca and Merck asserted the approval of LYNPARZA tablets for patients with Ovarian Cancer Read more